Study to evaluate the effect of six cycles of treatment with a combined oral contraceptive (EE 0.30 mg/DRSP 3 mg) on quality of life.
The purpose of this study is to evaluate the effects on the quality of life and BMI of new contraceptives.
- Female requiring contraceptives. - Aged 18 to 35 if a non-smoker, aged 18 to 30 if a smoker. - Regular menstrual cycle (defined as duration of 28 +/- 5 days).
- No Contraindication for OC use
A multicentre, open, uncontrolled study to assess quality of life during six cycles (24 weeks) of treatment with an oral contraceptive containing 30 µg of ethinylestradiol and 3 mg of drospirenone (Yasmin).
Single Group Assignment